Latest Administration News

ChemX Materials Limited has successfully completed its voluntary administration process with creditors approving restructuring agreements for both the parent company and its subsidiary HiPurA Pty Ltd. This marks a significant step towards stabilising operations and returning control to the board.

ChemX Materials Limited has emerged from voluntary administration following a Deed of Company Arrangement, while securing a significant Japanese patent for its HiPurA® High Purity Alumina process.

EPX Limited has submitted a proposal to acquire WattWatchers Pty Limited through a Deed of Company Arrangement, pending creditor approval. The move aims to integrate WattWatchers’ real-time energy monitoring solutions with EPX’s advanced building performance platform.

Lifestyle Communities is extending an option for existing homeowners to adopt a revised Deferred Management Fee model following a pivotal VCAT ruling, aiming to enhance transparency and goodwill regardless of the appeal outcome.

Felix Gold Limited has successfully raised $18 million through a placement to fund exploration and advance near-term military-grade antimony production in Alaska. The capital injection positions the company to capitalize on strategic supply opportunities amid global market shifts.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

DMC Mining's progress in Guinea is stalled as the government halts new exploration licences until after the December presidential election, prompting a 12-month extension on acquisition terms.

Imugene has secured FDA backing to advance its allogeneic CAR T therapy, azer-cel, into a pivotal Phase 3 trial targeting difficult-to-treat diffuse large B-cell lymphoma (DLBCL), including patients relapsed after prior CAR-T treatment.

Chimeric Therapeutics has won FDA Orphan Drug Designation for its CHM CDH17 CAR-T therapy targeting gastric cancer, advancing its clinical development with regulatory incentives and potential market exclusivity.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Audeara Limited has secured its largest-ever Australian wholesale purchase order worth $560,000, driving year-to-date wholesale revenues to $1.75 million and matching full FY25 figures. The company is also expanding manufacturing into China, signaling growing international ambitions.

Island Pharmaceuticals has been granted a pivotal US patent extending protection for its antiviral drug Galidesivir as a Covid-19 treatment until 2042, reinforcing its strategic position in the antiviral market.